New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides
摘要:
Hypoxic cells which are common feature of solid tumors are resistant to both anticancer drugs and radiation therapy. Thus, the identification of drugs with the selective toxicity toward hypoxic cells is an important target in anticancer chemotherapy. Tirapazamine has been shown to be an efficient and selective cytotoxin after bioreductive activation in hypoxic cells which is thought to be due to the presence of the 1,4-di-N-oxide. A new series of quinoxaline 1,4-di-N-oxides and fused quinoxaline di-N-oxides were synthesized and evaluated for hypoxic-cytotoxic activity on EAC cell line. Compound 10a was the most potent cytotoxin IC50 0.9 mu g/mL, potency 75 mu g/mL, and was approximately 15 times more selective cytotoxin (HCR > 111) than 3-aminoquinoxaline-2-carbonitrile which has been used as a standard (HCR > 7.5). Compounds 4 and 3a,b were more selective than the standard. In addition, antitumor activity against Hepg2 (liver) and U251 (brain) human cell lines was evaluated, compounds 9c and 8a were the most active against Hepg2 with IC50 values 1.9 and 2.9 mu g/mL, respectively, however, all the tested compounds were nontoxic against U251 cell line. (c) 2006 Elsevier Ltd. All rights reserved.
METHOD FOR TREATING A TUMOUR DISEASE AND METHOD FOR SELECTIVELY INHIBITING TUMOUR CELL GROWTH USING A QUINOXALINE-1,4-DIOXIDE DERIVATIVE
申请人:OOO "A-Laboratory"
公开号:EP3138565A1
公开(公告)日:2017-03-08
The present invention relates to the fields of pharmacology and medicine, in particular, to the medical application of 6,7-difluoro-3-phenyl-2-cyanoquinoxaline 1,4-dioxide of formula I:
for inhibition of tumor cell growth or treatment of tumor diseases.
New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides
作者:Kamelia M. Amin、Magda M.F. Ismail、Eman Noaman、Dalia H. Soliman、Yousry A. Ammar
DOI:10.1016/j.bmc.2006.06.038
日期:2006.10
Hypoxic cells which are common feature of solid tumors are resistant to both anticancer drugs and radiation therapy. Thus, the identification of drugs with the selective toxicity toward hypoxic cells is an important target in anticancer chemotherapy. Tirapazamine has been shown to be an efficient and selective cytotoxin after bioreductive activation in hypoxic cells which is thought to be due to the presence of the 1,4-di-N-oxide. A new series of quinoxaline 1,4-di-N-oxides and fused quinoxaline di-N-oxides were synthesized and evaluated for hypoxic-cytotoxic activity on EAC cell line. Compound 10a was the most potent cytotoxin IC50 0.9 mu g/mL, potency 75 mu g/mL, and was approximately 15 times more selective cytotoxin (HCR > 111) than 3-aminoquinoxaline-2-carbonitrile which has been used as a standard (HCR > 7.5). Compounds 4 and 3a,b were more selective than the standard. In addition, antitumor activity against Hepg2 (liver) and U251 (brain) human cell lines was evaluated, compounds 9c and 8a were the most active against Hepg2 with IC50 values 1.9 and 2.9 mu g/mL, respectively, however, all the tested compounds were nontoxic against U251 cell line. (c) 2006 Elsevier Ltd. All rights reserved.